2019
DOI: 10.1016/j.dsx.2018.10.008
|View full text |Cite
|
Sign up to set email alerts
|

Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
187
0
12

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 322 publications
(199 citation statements)
references
References 90 publications
0
187
0
12
Order By: Relevance
“…Studies of the natural process of the disease have shown that it is characterized by a progressive prostration of cells. People affected by DM type 2 are insulin-resistant and usually have a metabolic syndrome, a multifactorial intervention including aggressive treatment of dyslipidaemia and arterial hypertension [ 25 ]. One of the therapeutic approaches for treating type 2 DM is to reduce the post-prandial glucose levels.…”
Section: Resultsmentioning
confidence: 99%
“…Studies of the natural process of the disease have shown that it is characterized by a progressive prostration of cells. People affected by DM type 2 are insulin-resistant and usually have a metabolic syndrome, a multifactorial intervention including aggressive treatment of dyslipidaemia and arterial hypertension [ 25 ]. One of the therapeutic approaches for treating type 2 DM is to reduce the post-prandial glucose levels.…”
Section: Resultsmentioning
confidence: 99%
“…Diabetes mellitus (DM) is one of the major causes of premature illness and mortality worldwide (Federation, 2009). High blood glucose levels and glucose intolerance, as a consequence of a defective insulin production/secretion by pancreatic β cells (βcells) or insulin sensitivity (Stumvoll et al, 2005;Tan et al, 2019), are the typical clinical features of the disease. In T2DM, impairment and loss of β-cell mass has been associated with diverse pathological phenomena, including glucolipotoxicity, islet cholesterol accumulation, and islet inflammation (Poitout and Robertson, 2002;Ishikawa et al, 2008;Brunham et al, 2010;Donath and Shoelson, 2011).…”
Section: Iapp and Diabetesmentioning
confidence: 99%
“…Type 2 diabetes (T2D) is much more common and is caused by insulin resistance of surrounding tissues, such as the liver, muscle and fat. Currently, the major approaches used to alleviate the symptoms of diabetes are the transplantation of cadaveric islets and exogenous insulin injection, but these have the disadvantages of donor shortage and inaccurate glucose control, respectively (Aguayo-Mazzucato and Bonner-Weir, 2018;Tan et al, 2019). Sustainable sources of functional β cells or islets represent a promising method for improved diabetes treatment.…”
Section: Introductionmentioning
confidence: 99%